Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1B
In a significant move, Italian pharmaceutical company Angelini Pharma is set to purchase Catalyst Pharmaceuticals for $4.1 billion, offering $31.50 per share in cash. This transaction signifies Angelini's first venture into the U.S. pharmaceutical sector.
Key facts
- Angelini Pharma is acquiring Catalyst Pharmaceuticals
- Deal valued at $4.1 billion
- Purchase price is $31.50 per share in cash
- Acquisition marks Angelini's entry into the U.S. pharmaceutical market
Entities
Institutions
- Angelini Pharma
- Catalyst Pharmaceuticals
Locations
- Italy
- United States
Sources
- Quartz —